Presence of teratoma in orchiectomy specimen increases the need for postchemotherapy RPLND.

[1]  R. Motzer,et al.  Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection. , 2006, The Journal of urology.

[2]  R. Motzer,et al.  Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors. , 2003, The Journal of urology.

[3]  H. Ozen,et al.  Resection of residual masses alone: an alternative in surgical therapy of metastatic testicular germ cell tumors after chemotherapy. , 2001, Urology.

[4]  J. Donohue,et al.  Integration of surgery and systemic therapy: results and principles of integration. , 1998, Seminars in urologic oncology.

[5]  L. Einhorn,et al.  Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Culine,et al.  Evaluation of primary standard cisplatin-based chemotherapy for clinical stage II non-seminomatous germ cell tumours of the testis. , 1997, British journal of urology.

[7]  J. Habbema,et al.  Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular cancer. , 1996, British Journal of Cancer.

[8]  M. Gleave,et al.  Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy , 1996, Cancer.

[9]  T. Ulbright,et al.  Teratoma in the Orchiectomy Specimen and Volume of Metastasis are Predictors of Retroperitoneal Teratoma in Post-Chemotherapy Nonseminomatous Testis Cancer , 1996 .

[10]  H. Zincke,et al.  Primary chemotherapy for clinical stage II nonseminomatous germ cell testicular tumors: selection criteria and long-term results. , 1995, Mayo Clinic proceedings.

[11]  J P Donohue,et al.  Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. Ozen,et al.  Postchemotherapeutic surgery for metastatic testicular germ cell tumors: results of extended primary chemotherapy and limited surgery. , 1994, Urology.

[13]  S. Fosså,et al.  Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Mead,et al.  The growing teratoma syndrome. , 1991, British journal of urology.

[15]  C. Logothetis,et al.  Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Richie,et al.  Residual abdominal masses after chemotherapy for nonseminomatous testicular cancer: correlation of CT and histology. , 1985, AJR. American journal of roentgenology.

[17]  J. Habbema,et al.  Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Motzer,et al.  Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. , 1998, The Journal of urology.

[19]  D. Ondruš,et al.  Postchemotherapy surgery in nonseminomatous testicular tumors. , 1996, European urology.

[20]  D. Dearnaley,et al.  Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis. , 1994, The Journal of urology.